Breaking Down SG&A Expenses: Amgen Inc. vs Viking Therapeutics, Inc.

Biotech Giants: Amgen vs Viking SG&A Expense Trends

__timestampAmgen Inc.Viking Therapeutics, Inc.
Wednesday, January 1, 201446990000001244910
Thursday, January 1, 201548460000005029636
Friday, January 1, 201650620000004846776
Sunday, January 1, 201748700000005329003
Monday, January 1, 201853320000007121000
Tuesday, January 1, 201951500000009128000
Wednesday, January 1, 2020573000000010731000
Friday, January 1, 2021536800000010701000
Saturday, January 1, 2022541400000016121000
Sunday, January 1, 2023617900000037021000
Monday, January 1, 20247096000000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: Amgen Inc. vs Viking Therapeutics, Inc.

In the competitive world of biotechnology, understanding the financial dynamics of industry leaders is crucial. Amgen Inc., a titan in the field, has consistently demonstrated robust financial health, particularly in its Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, marking a 31% rise over the decade.

In stark contrast, Viking Therapeutics, Inc., a smaller player, has seen its SG&A expenses grow from a modest $1.2 million in 2014 to $37 million in 2023. This represents a staggering increase of over 2,800%, reflecting its aggressive expansion and investment in growth.

This comparison highlights the differing strategies of established giants and emerging innovators in the biotech sector, offering valuable insights into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025